113 related articles for article (PubMed ID: 3107626)
1. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
Ritschel WA; Kuo BS
Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
[TBL] [Abstract][Full Text] [Related]
2. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
Kuo BS; Ritschel WA
Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
Pedersen AK; FitzGerald GA
Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
Del Maschio A; Livio M; Cerletti C; De Gaetano G
Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
[TBL] [Abstract][Full Text] [Related]
6. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
Butler KD; Wallis RB; White AM
Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
[TBL] [Abstract][Full Text] [Related]
7. New metabolites of sulfinpyrazone in man.
Dieterle W; Faigle JW; Moppert J
Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
[TBL] [Abstract][Full Text] [Related]
8. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
Maguire ED; Pay GF; Wallis RB; White AM
Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
[No Abstract] [Full Text] [Related]
9. Effects of sulfinpyrazone and its metabolite G25671 on platelet activation and desensitization and on bronchoconstriction induced by the prostaglandin endoperoxide analog U46619.
Hatmi M; del Maschio A; Lefort J; de gaetano G; Vargaftig BB; Cerletti C
J Pharmacol Exp Ther; 1987 May; 241(2):623-7. PubMed ID: 3106620
[TBL] [Abstract][Full Text] [Related]
10. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
Pay GF; Wallis RB; Zelaschi D
Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
[TBL] [Abstract][Full Text] [Related]
11. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo.
Buchanan MR; Rosenfeld J; Hirsh J
Thromb Res; 1978 Nov; 13(5):883-92. PubMed ID: 741458
[No Abstract] [Full Text] [Related]
12. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
Pay GF; Wallis RB; Zelaschi D
Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
[No Abstract] [Full Text] [Related]
13. Species differences in the disposition and metabolism of sulfinpyrazone.
Dieterle W; Faigle JW
Xenobiotica; 1981 Aug; 11(8):559-68. PubMed ID: 7303725
[TBL] [Abstract][Full Text] [Related]
14. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
[TBL] [Abstract][Full Text] [Related]
15. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
Lorenz R; Siess W; Weber PC
Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
[TBL] [Abstract][Full Text] [Related]
16. Sulphinpyrazone inhibits platelet function and enhances blood fibrinolytic activity in the rat.
Hussaini IM; Moore PK
Thromb Res; 1988 Nov; 52(4):337-41. PubMed ID: 3201405
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.
Ritschel WA
Pharm Res; 1986 Jun; 3(3):173-7. PubMed ID: 24271525
[TBL] [Abstract][Full Text] [Related]
18. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro.
Pfister B; Godbillon J; Colussi D; Imhof P
Thromb Res; 1980 Apr 1-15; 18(1-2):89-99. PubMed ID: 7404507
[No Abstract] [Full Text] [Related]
19. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins.
Chang WC; Hsu FL
Prostaglandins Leukot Essent Fatty Acids; 1989 Dec; 38(3):181-8. PubMed ID: 2516322
[TBL] [Abstract][Full Text] [Related]
20. Effect of acetylsalicylic acid, sulfinpyrazone and their combination on collagen-induced platelet aggregation in guinea pigs.
Wong LT; Zawidzka Z; Thomas BH
Pharmacol Res Commun; 1978 Nov; 10(10):939-49. PubMed ID: 733865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
